Brian Lee

Alston & Bird

+ Follow Contact

Latest Posts › Medicare

Share:

Potential Medicare Physician Fee Schedule Reform in the Last Weeks of the 118th Congress

A flurry of bills to reform the Medicare Physician Fee Schedule (PFS) faces the lame duck Congress. Our Health Care Group investigates how those reforms could take shape and which, if any, could find their way through the...more

12/5/2024 / Centers for Medicare & Medicaid Services (CMS) , Health Care Providers , Healthcare , Lame Duck Session , Legislative Agendas , Medicare , Physician Fee Schedule

Is Medicare Physician Fee Schedule Reform on the Horizon?

The decreasing value of Medicare reimbursements for physicians has caught the attention of a group of doctors in Congress. Our Heath Care Group explains how draft legislation would stabilize the Physician Fee Schedule (PFS)...more

10/31/2023 / Centers for Medicare & Medicaid Services (CMS) , Health Care Providers , Inpatient Prospective Payment System (IPPS) , Medicare , Physician Fee Schedule , Physicians

Sequester Relief Extension Highlights Potential Reimbursement Cliff for Medicare Providers in 2022

Medicare providers face a nearly 10% reimbursement cut in 2022. Our Health Care Legislative & Public Policy Team does the math and explains how a combination of sequester cuts and expiring reimbursement support could bring a...more

4/23/2021 / Health Care Providers , Medicare , Provider Payments , Reimbursements , Sequestration

CMS Announces New Repayment Terms for Medicare Accelerated and Advance Payment Program Loans

Our Health Care Group details how changes by the Centers for Medicare & Medicaid Services to the AAP loan program delays repayment obligations for all health care providers and suppliers that received AAP loans during the...more

10/13/2020 / Advanced Payment Program , CARES Act , Centers for Medicare & Medicaid Services (CMS) , Coronavirus/COVID-19 , Financial Distress , Medicare

Updates on Biosimilar Reimbursement Pathways in the Face of a Changing Market

Though the biosimilars market has evolved, and more companies are seizing the opportunities, reimbursement regulations have been unclear at best. Our Health Care Group untangles the latest rules from the Centers for Medicare...more

1/25/2018 / Biosimilars , Centers for Medicare & Medicaid Services (CMS) , Food and Drug Administration (FDA) , Health Care Providers , Medicare , Medicare Part B , Medicare Part D , Pharmaceutical Industry , Prescription Drug Coverage , Prescription Drugs

5 Results

View per page

Page: of 1